Stock HOLX HOLOGIC, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hologic, Inc.

Equities

HOLX

US4364401012

Advanced Medical Equipment & Technology

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
75.98 USD +0.36% Intraday chart for Hologic, Inc. +0.80% +6.34%
Apr. 11 Bayer and Hologic Collaborates to Deliver Contrast-Enhanced Mammography CI
Apr. 09 Transcript : Hologic, Inc. Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-09-2024 11:45 AM

Valuation

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 13,496 17,215 18,710 16,108 16,999 17,835 - -
Enterprise Value (EV) 1 15,949 19,553 20,565 16,592 17,095 17,282 16,465 15,148
P/E ratio -337 x 15.8 x 10.2 x 12.6 x 37.9 x 22.8 x 21.2 x 19.3 x
Yield - - - - - - - -
Capitalization / Revenue 4.01 x 4.56 x 3.32 x 3.31 x 4.22 x 4.42 x 4.2 x 3.96 x
EV / Revenue 4.74 x 5.18 x 3.65 x 3.41 x 4.24 x 4.29 x 3.88 x 3.37 x
EV / EBITDA 14.9 x 12.6 x 6.96 x 7.89 x 13.1 x 13.1 x 11.6 x 10 x
EV / FCF 26.9 x 26.4 x 9.21 x 8.07 x 17.8 x 18.2 x 15.7 x 13.7 x
FCF Yield 3.71% 3.79% 10.9% 12.4% 5.61% 5.49% 6.35% 7.28%
Price to Book 6 x 6.32 x 4.44 x 3.36 x 3.44 x 3.61 x 3.1 x 2.69 x
Nbr of stocks (in thousands) 267,306 258,985 253,487 249,653 244,942 234,732 - -
Reference price 2 50.49 66.47 73.81 64.52 69.40 75.98 75.98 75.98
Announcement Date 11/6/19 11/4/20 11/1/21 10/31/22 11/9/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 3,367 3,776 5,632 4,863 4,030 4,031 4,248 4,500
EBITDA 1 1,069 1,558 2,956 2,104 1,307 1,321 1,419 1,510
EBIT 1 972.2 1,467 2,866 1,998 1,207 1,222 1,321 1,422
Operating Margin 28.87% 38.84% 50.88% 41.08% 29.95% 30.31% 31.09% 31.61%
Earnings before Tax (EBT) 1 -95.3 1,002 2,361 1,588 676.1 907.7 1,063 1,186
Net income 1 -40.2 1,115 1,872 1,302 456 797.9 844.5 923.2
Net margin -1.19% 29.53% 33.23% 26.77% 11.31% 19.79% 19.88% 20.52%
EPS 2 -0.1500 4.210 7.210 5.130 1.830 3.338 3.579 3.945
Free Cash Flow 1 592.5 740.2 2,234 2,055 959.4 948.9 1,045 1,102
FCF margin 17.6% 19.6% 39.66% 42.26% 23.8% 23.54% 24.61% 24.49%
FCF Conversion (EBITDA) 55.43% 47.52% 75.55% 97.69% 73.43% 71.81% 73.68% 73%
FCF Conversion (Net income) - 66.37% 119.35% 157.84% 210.39% 118.93% 123.79% 119.39%
Dividend per Share 2 - - - - - - - -
Announcement Date 11/6/19 11/4/20 11/1/21 10/31/22 11/9/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: September 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 1,317 1,471 1,436 1,003 953.3 1,074 1,026 984.4 945.3 1,013 1,002 1,010 1,005 1,065 1,053
EBITDA 1 575.8 752.3 703.6 348.3 299.5 361 345.4 311.9 288.3 315 326.2 339.9 345.4 352 352.1
EBIT 1 560 727.3 680.7 323.8 265.7 334.1 320.9 284.5 267.7 288.5 301.7 314.2 318.4 326.5 326.9
Operating Margin 42.53% 49.44% 47.41% 32.29% 27.87% 31.1% 31.26% 28.9% 28.32% 28.48% 30.13% 31.1% 31.68% 30.66% 31.05%
Earnings before Tax (EBT) 1 410.6 621.9 574.4 248.4 143.4 239.1 279.3 12.1 145.6 191.3 232.2 245.3 253.4 264.4 263.3
Net income 1 328.8 499.2 455.7 228.4 118.7 187.4 218.5 -40.5 90.6 246.5 178.8 192.7 197.9 203.4 204.3
Net margin 24.97% 33.93% 31.74% 22.78% 12.45% 17.45% 21.29% -4.11% 9.58% 24.33% 17.85% 19.07% 19.7% 19.1% 19.4%
EPS 2 1.280 1.950 1.800 0.9000 0.4700 0.7500 0.8700 -0.1600 0.3700 1.030 0.7903 0.8130 0.8332 0.8630 0.8685
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 11/1/21 2/2/22 4/27/22 7/27/22 10/31/22 2/1/23 5/1/23 7/31/23 11/9/23 2/1/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 2,453 2,338 1,855 484 95.7 - - -
Net Cash position 1 - - - - - 553 1,370 2,687
Leverage (Debt/EBITDA) 2.295 x 1.501 x 0.6274 x 0.23 x 0.0732 x - - -
Free Cash Flow 1 593 740 2,234 2,055 959 949 1,045 1,102
ROE (net income / shareholders' equity) 28% 46.3% 54.1% 33.6% 19.9% 18.5% 18.7% 18%
ROA (Net income/ Total Assets) 9.53% 16.4% 23.2% 14.5% 10.8% 9.1% 9.51% 8%
Assets 1 -422 6,819 8,056 8,996 4,219 8,772 8,877 11,540
Book Value Per Share 2 8.410 10.50 16.60 19.20 20.20 21.00 24.50 28.30
Cash Flow per Share 2 2.410 3.390 8.970 8.370 4.220 4.680 6.190 5.110
Capex 1 57 98.3 96.8 70.6 91.8 89.9 95.5 109
Capex / Sales 1.69% 2.6% 1.72% 1.45% 2.28% 2.23% 2.25% 2.41%
Announcement Date 11/6/19 11/4/20 11/1/21 10/31/22 11/9/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Hologic, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
75.98 USD
Average target price
84.27 USD
Spread / Average Target
+10.92%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
HOLOGIC, INC. Stock Hologic, Inc.
+6.34% 17.83B
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.07% 219B
DANAHER CORPORATION Stock Danaher Corporation
+6.59% 183B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.26% 133B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+26.57% 108B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+13.35% 52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-0.62% 48.2B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-0.93% 40.37B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+11.54% 39.35B
RESMED, INC. Stock ResMed, Inc.
+26.76% 32.03B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. HOLX Stock
  4. Financials Hologic, Inc.